Ginkgo bioworks reports first quarter 2024 financial results

Ginkgo announces several initiatives to accelerate path to adjusted ebitda breakeven by end of 2026 initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 boston , may 9, 2024 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended march 31, 2024. the update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking